祥生医疗
(688358)
| 流通市值：34.30亿 | | | 总市值：34.30亿 |
| 流通股本：1.12亿 | | | 总股本：1.12亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 236,154,283.59 | 127,713,897.36 | 468,697,167.84 | 362,245,220.14 |
| 营业收入 | 236,154,283.59 | 127,713,897.36 | 468,697,167.84 | 362,245,220.14 |
| 二、营业总成本 | 161,873,289.95 | 83,307,450.65 | 327,751,586.51 | 265,916,746.04 |
| 营业成本 | 92,936,644.25 | 49,387,867.06 | 192,382,017.25 | 147,964,861.72 |
| 税金及附加 | 1,179,164.15 | 604,543.03 | 4,046,143.78 | 3,612,804.07 |
| 销售费用 | 27,924,657.97 | 12,849,734.01 | 54,999,266.7 | 39,476,204.72 |
| 管理费用 | 15,529,167.97 | 7,770,022.73 | 37,633,830.11 | 27,172,040.53 |
| 研发费用 | 37,613,050.61 | 17,456,907.97 | 79,633,906.16 | 61,760,390.24 |
| 财务费用 | -13,309,395 | -4,761,624.15 | -40,943,577.49 | -14,069,555.24 |
| 其中:利息费用 | 92,215.18 | 69,941.5 | 378,743.71 | 297,302.28 |
| 其中:利息收入 | 16,673,694.95 | 7,197,249.92 | 31,197,587.65 | 20,523,681.22 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 95,763.77 | 141,979.83 | 170,984.75 | 263,783.4 |
| 加:投资收益 | 1,953,564.51 | 910,805.64 | 6,119,986.84 | 4,784,941.62 |
| 资产处置收益 | 3,156,901.27 | 993,435.76 | 4,612,503.98 | 3,149,775.04 |
| 资产减值损失(新) | -2,501,971.97 | -571,804.57 | -4,561,745.68 | -974,947.4 |
| 信用减值损失(新) | -2,087,096.45 | -1,262,698.66 | -1,973,356.27 | -3,864,255.69 |
| 其他收益 | 4,770,022.11 | 2,578,545.44 | 11,986,108.28 | 8,203,394.72 |
| 四、营业利润 | 79,668,176.88 | 47,196,710.15 | 157,300,063.23 | 107,891,165.79 |
| 加:营业外收入 | 148,333.26 | 311.99 | 94,545.68 | 7,000.6 |
| 减:营业外支出 | 314,566.58 | 119,462.34 | 548,386.04 | 245,441.91 |
| 五、利润总额 | 79,501,943.56 | 47,077,559.8 | 156,846,222.87 | 107,652,724.48 |
| 减:所得税费用 | 9,805,622.68 | 5,463,029.48 | 16,341,080.29 | 9,244,171.78 |
| 六、净利润 | 69,696,320.88 | 41,614,530.32 | 140,505,142.58 | 98,408,552.7 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 69,696,320.88 | 41,614,530.32 | 140,505,142.58 | 98,408,552.7 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 69,696,320.88 | 41,614,530.32 | 140,505,142.58 | 98,408,552.7 |
| 扣除非经常损益后的净利润 | 63,825,981.39 | 38,872,803.38 | 127,117,573.54 | 89,369,760.75 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.62 | 0.37 | 1.26 | 0.88 |
| (二)稀释每股收益 | 0.62 | 0.37 | 1.26 | 0.88 |
| 八、其他综合收益 | -1,534,028.17 | -518,532.97 | 1,925,329.89 | -3,326,913.66 |
| 归属于母公司股东的其他综合收益 | -1,534,028.17 | -518,532.97 | 1,925,329.89 | -3,326,913.66 |
| 九、综合收益总额 | 68,162,292.71 | 41,095,997.35 | 142,430,472.47 | 95,081,639.04 |
| 归属于母公司股东的综合收益总额 | 68,162,292.71 | 41,095,997.35 | 142,430,472.47 | 95,081,639.04 |
| 公告日期 | 2025-08-29 | 2025-04-25 | 2025-04-25 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |